Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Deferred Taxes (2024 - 2025)

Cytek Biosciences' Deferred Taxes history spans 2 years, with the latest figure at $38.6 million for Q4 2025.

  • For Q4 2025, Deferred Taxes rose 1436.66% year-over-year to $38.6 million; the TTM value through Dec 2025 reached $33.6 million, up 1262.75%, while the annual FY2025 figure was $33.6 million, 1262.75% up from the prior year.
  • Deferred Taxes reached $38.6 million in Q4 2025 per CTKB's latest filing, up from -$2.6 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $38.6 million in Q4 2025 to a low of -$2.9 million in Q4 2024.